Publication Beamlines Strategic Pillar
Cregg, James; Pota, Kristof; Tomlinson, Aidan C. A.; Yano, Jason; Marquez, Abby et al. (2025). Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers. Journal of Medicinal Chemistry . 10.1021/acs.jmedchem.4c02313. [PDB: 9bfv, 9bfw] CMCF-ID Health
Cregg, James; Edwards, Anne V.; Chang, Stephanie; Lee, Bianca J.; Knox, John E. et al. (2025). Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. Journal of Medicinal Chemistry . 10.1021/acs.jmedchem.4c02314. [PDB: 9bg0, 9bg2, 9bg3, 9bg4, 9bg5, 9bg6, 9bg8, 9bga, 9bgb, 9bgc, 9bgd] CMCF-ID Health
Cottrell, Kevin M.; Briggs, Kimberly J.; Whittington, Douglas A.; Jahic, Haris; Ali, Janid A. et al. (2024). Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers. Journal of Medicinal Chemistry 67(8) , 6064-6080. 10.1021/acs.jmedchem.4c00133. [PDB: 8veu] CMCF-ID Health